Literature DB >> 23141221

Re: Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.

Samir S Taneja.   

Abstract

Entities:  

Year:  2012        PMID: 23141221     DOI: 10.1016/j.juro.2012.08.170

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  1 in total

1.  Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report.

Authors:  Mona Passler; Eliane T Taube; Jalid Sehouli; Klaus Pietzner
Journal:  World J Clin Oncol       Date:  2019-07-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.